Screener / SEC EDGAR /CIK 0001635088 /10-K filed May 20, 2026, compared with May 29, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

Roivant Sciences Ltd. ROIV

Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. 10-K, Item 1

Headquarters
London
CEO
Matthew Gline
Next results
around Feb 5, 2027
Compare with peers Embed

ROIV among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: -71.6%, above 1% of 154 peers (their median 10.5%) REVENUE GROWTH -71.6% · above 1% Net margin: -838.2%, above 1% of 153 peers (their median 6.8%) NET MARGIN -838.2% · above 1% FCF margin: -81.2%, above 6% of 144 peers (their median 10.1%) FCF MARGIN -81.2% · above 6%
ROIV Peer median Below the median

What changed

65 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed May 20, 2026 against May 29, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

9 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 8 checks found nothing to note

  • Cash from operations lower than net income
    Cash from operations −$750.3M vs net income −$299.8M (FY ending Mar 31, 2026)
  • Same auditor in both 10-Ks: Ernst & Young LLP
7 more checks with nothing to note
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Clinical Trial Accrual; Valuation of Investment in Datavant
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

65 paragraphs in Risk Factors that were not in the 10-K filed May 29, 2025. Quoted as filed.

All 65 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed May 29, 2025 10-K, ITEM 1A
    We also face significant competition for investment opportunities. A number of companies compete with us for such opportunities. These companies may possess greater financial or technical resources than we do. If we are unable to
  2. Item 1A · new paragraph · not in the 10-K filed May 29, 2025 10-K, ITEM 1A
    Immunovant relies on the HanAll Agreement to provide the rights to the core intellectual property relating to IMVT-1402 and batoclimab. Any termination or loss of significant rights under the HanAll Agreement could adversely affect Immunovant’s development or commercialization of IMVT-1402. Our subsidiary Immunovant holds the…
  3. Item 1A · new paragraph · not in the 10-K filed May 29, 2025 10-K, ITEM 1A
    Immunovant shared top-line results from the two batoclimab Phase 3 TED studies concurrently in April 2026. Neither study achieved its primary endpoint, leading Immunovant to make a decision to discontinue further development of batoclimab across all indications to focus fully on IMVT-1402. HanAll has a variety of interests in the…
  4. Item 1A · new paragraph · not in the 10-K filed May 29, 2025 10-K, ITEM 1A
    Changes in tariffs and other governmental trade policies could negatively affect our business and results of operations. Recent governmental actions and proposals relating to tariffs and other trade policies have created uncertainty about future trading arrangements and the possibility of jurisdictions imposing or increasing tariffs on…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2023FY2024FY2025FY2026
Revenue$31.5M$32.7M$29.1M$8.3M
Net income−$1.0B$4.3B−$172.0M−$299.8M
Operating cash flow−$843.4M−$765.3M−$839.5M−$750.3M
Free cash flow−$856.1M−$766.6M−$844.0M−$758.6M

Revenue, FY2021 to FY2026

Ten fiscal years, each from its own 10-K · XBRL · USD

$8.3M ▼ 71.6% in FY2026

FY2021FY2022FY2023FY2024FY2025FY2026
Every number, year by year

Recent filings

18 filings in the last 30 days · SEC EDGAR

All filings
13 more

About the company

Roivant Sciences Ltd., London · from the 10-K filed May 20, 2026

Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 currently under review at the FDA for the treatment of dermatomyositis and also in late stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung di…

Headquarters
London
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
March 31
Last results
Nov 9, 2026
Incorporated in
Bermuda

Email alerts

Sources

The 10-K filed May 20, 2026 (open at SEC), compared with the 10-K filed May 29, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ROIV/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.